BiotechTube

Aflibercept

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Exudative Macular Degeneration

Conditions

Exudative Macular Degeneration

Trial Timeline

Jun 1, 2012 → Dec 1, 2015

NCT ID
NCT01617148

About Aflibercept

Aflibercept is a approved stage product being developed by Regeneron Pharmaceuticals for Exudative Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT01617148. Target conditions include Exudative Macular Degeneration.

What happened to similar drugs?

4 of 4 similar drugs in Exudative Macular Degeneration were approved

Approved (4) Terminated (0) Active (0)
✅ranibizumabNovartisApproved
✅ranibizumabNovartisApproved
✅afliberceptBayerApproved
✅Vascular endothelial growth factor trap-eyeBayerApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (14)

NCT IDPhaseStatus
NCT01714115Pre-clinicalCompleted
NCT04101721Phase 3Completed
NCT03396861Phase 1Terminated
NCT03085784Phase 2UNKNOWN
NCT02863354Phase 2Completed
NCT02559180ApprovedCompleted
NCT02503540ApprovedCompleted
NCT02299336ApprovedCompleted
NCT02204683Phase 1Completed
NCT01857544ApprovedUNKNOWN
NCT01722656ApprovedCompleted
NCT01670162ApprovedUNKNOWN
NCT01617148ApprovedCompleted
NCT01495208ApprovedWithdrawn

Competing Products

5 competing products in Exudative Macular Degeneration

See all competitors
ProductCompanyStageHype Score
ranibizumabNovartisApproved
43
ranibizumabNovartisApproved
39
LHA510 ophthalmic suspension + LHA510 vehicle + Ranibizumab ophthalmic solutionNovartisPhase 2
35
afliberceptBayerApproved
40
Vascular endothelial growth factor trap-eyeBayerApproved
40